Pomalidomide-d5 |
Catalog No.GC47965 |
An internal standard for the quantification of pomalidomide
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1377838-49-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Pomalidomide-d5 is intended for use as an internal standard for the quantification of pomalidomide by GC- or LC-MS. Pomalidomide is an analog of thalidomide that inhibits the E3 ligase protein cereblon (CRBN) with an IC50 value of approximately 3 µM for the human recombinant CRBN-DNA damage binding protein-1 (CRBN-DDB1) complex.1 It inhibits autoubiquitination of CRBN in HEK293T cells expressing CRBN but not those expressing a thalidomide-binding defective CRBN mutation. It inhibits proliferation of U266 myeloma cells when used at concentrations ranging from 0.1 to 10 µM. Pomalidomide also has antiangiogenic and immunomodulatory effects against myeloma cells, modulating cell adhesion, decreasing production of key pro-survival cytokines, including TNF-α, and triggering the activation of caspase-8.2,3 Pomalidomide (3 mg/kg per day), in combination with dexamethasone, reduces tumor growth in a H929 R10-1 lenalidomide-resistant mouse xenograft model.4 Formulations containing pomalidomide have been used in the treatment of multiple myeloma.
1.Lopez-Girona, A., Mendy, D., Miller, K., et al.Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideLeukemia26(11)2326-2335(2012) 2.Zhu, Y.X., Kortuem, K.M., and Stewart, A.K.Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myelomaLeukemia and Lymphoma54(4)683-687(2013) 3.Latif, T., Chauhan, N., Khan, R., et al.Thalidomide and its analogues in the treatment of multiple myelomaExp.Hermatol.Oncol.1(1)27(2012) 4.Rychak, E., Mendy, D., Shi, T., et al.Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myelomaBr. J. Haematol.172(6)889-901(2016)
Cas No. | 1377838-49-7 | SDF | |
Canonical SMILES | NC1=C2C(C(N(C3([2H])C(NC(C([2H])([2H])C3([2H])[2H])=O)=O)C2=O)=O)=CC=C1 | ||
Formula | C13H6D5N3O4 | M.Wt | 278.3 |
Solubility | DMF: 10 mg/ml,DMSO: 15 mg/ml | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.5932 mL | 17.9662 mL | 35.9324 mL |
5 mM | 0.7186 mL | 3.5932 mL | 7.1865 mL |
10 mM | 0.3593 mL | 1.7966 mL | 3.5932 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 12 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *